secwatch.observer — SEC 8-K summary
======================================

Issuer:     ImageneBio, Inc. (IMA)
CIK:        0001835579
Form:       8-K
Filed at:   2026-03-10T23:59:59+00:00
Accession:  0001193125-26-099422
Event type: other_material
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ImageneBio reports Q4 2025 net loss $6.9M; cash $135.3M; Phase 2b ADAPTIVE on track for 2027
--------------------------------------------------------------------------------

- Cash, equivalents and marketable securities: $135.3M at Dec 31, 2025 vs $12.1M at Dec 31, 2024, after merger and $75M private placement.
- Net loss Q4 2025: $6.9M vs $4.8M Q4 2024, driven by post-merger operating costs and transaction expenses.
- Phase 2b ADAPTIVE trial (IMG-007 in atopic dermatitis) enrolling on schedule; blinded safety review found no pyrexia/chills/ulcers/malignancies.
- Appointed Dr. Ben Porter-Brown as CMO in Feb 2026; also added CEO, CSO, CTO, and an independent director during 2025.
- Submitted protocol amendment to expand dosing regimens, evaluate loading doses, and test patient-friendly intervals in ADAPTIVE.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1835579/000119312526099422/0001193125-26-099422-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1835579/000119312526099422/d130344d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-099422

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer